Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128615) titled 'A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: AstraZeneca
Condition:
Influenza A
Intervention:
Biological: AZD4117
Biological: AZD5315
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 19, 2025
Target Sample Size: 400
Countries of Recruitment:
United States
To know more, visit...